



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/91509/2017

European Medicines Agency decision

P/0071/2017

of 17 March 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for avelumab (EMEA-001849-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0071/2017

of 17 March 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral for avelumab (EMA-001849-PIP02-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Merck KGaA on 18 March 2016 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 January 2017, in accordance with Article 18 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for avelumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for avelumab, concentrate for solution for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Merck KGaA, Frankfurter Strasse 250, 64293 – Darmstadt, Germany.

EMA/PDCO/287040/2016
London, 27 January 2017

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-001849-PIP02-15

Scope of the application

Active substance(s):

Avelumab

Condition(s):

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)

Pharmaceutical form(s):

Concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

Merck KGaA

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Merck KGaA submitted for agreement to the European Medicines Agency on 18 March 2016 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 26 April 2016.

Supplementary information was provided by the applicant on 4 November 2016. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients from birth to less than 18 years old with a solid tumour as part of the first line treatment

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	3	Study 1 Exploratory toxicity/efficacy non-clinical study in a syngeneic mouse model. Study 2 Collection and analysis of data from literature and databases of paediatric tumour samples relative to tumour genetic mutations and tumour gene and neoantigens expression. Study 3 Non-clinical biomarker study in paediatric tumour tissues.
Clinical studies	2	Study 4 Open-label study to evaluate pharmacokinetics, pharmacodynamics, safety and anti-cancer activity of avelumab in paediatric patients from birth to less than 18 years of age with a refractory or relapsed solid tumour or for which no effective treatment is known (phase I), and to evaluate safety and efficacy in at least two expansion cohorts in selected tumour types (phase II).

		Study 5 Randomized, active-controlled study to evaluate efficacy and safety of avelumab in combination with standard of care in children from birth to less than 18 years of age with a paediatric solid tumour selected on the basis of the results of Study 1, Study 2. Study 3 and Study 4.
Extrapolation, modelling and simulation studies	1	Study 6 Adult population pharmacokinetic PK (POPPK) model study
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes